The Initial Commercial Success and Limitations of TIL Therapy

Iovance Biotherapeutics (NASDAQ: IOVA)'s Amtagvi (active ingredient: lifileucel) received FDA approval in February 2024 as a treatment for advanced melanoma, marking a milestone in the solid tumor cell therapy market. This is the first instance of a regulatory agency officially validating the clinical efficacy of patient-specific T-cell immune responses, garnering significant attention in the industry. However, the inherent characteristics of non-engineered TILs, such as severe systemic toxicity associated with high-dose interleukin-2 (IL-2) co-administration and high manufacturing costs of approximately $515,000, remain commercial limitations that need to be addressed.

The Rise of Genetically Modified TILs to Overcome Interleukin Toxicity

Next-generation player, Obsidian Therapeutics, presents an engineered TIL platform that eliminates the need for exogenous IL-2 administration through OBX-115, which is equipped with membrane-bound interleukin-15 (IL-15). This candidate has demonstrated an objective response rate (ORR) of 67% and two complete responses (CR) in a Phase 2 clinical trial, emerging as a potent alternative for melanoma patients who have failed prior treatments. Furthermore, the company is pursuing a merger with Galera Therapeutics (NASDAQ: OBX planned) and has secured $350 million in private placement funding, ensuring robust financial stability for clinical research through 2028.

Maximizing Immune Activation through CRISPR Gene Editing

KSQ Therapeutics is conducting a Phase 1 clinical trial of KSQ-001EX, which utilizes CRISPR/Cas9 technology to inactivate the immunosuppressive gene SOCS1. This platform is further enhanced with KSQ-004EX, a dual-targeting agent that simultaneously removes SOCS1 and Regnase-1, maximizing the cell's immune activity. This genetic modification aims to neutralize immune suppression mechanisms within the tumor microenvironment (TME), potentially offering a new breakthrough in the treatment of refractory solid tumors such as pancreatic cancer and colorectal cancer.

Overcoming Cold Tumors and Precision Cell Selection Technology

Curacell (Sweden) and AgonOx (USA) are focusing on 'cold tumors,' which have a limited presence of infiltrating T cells and exhibit extremely low response rates to immune checkpoint inhibitors. Curacell is actively conducting Phase 1/2 clinical trials of CC-38, which targets prostate cancer, based on the CytoPLY cell activation platform, addressing unmet needs. Meanwhile, AgonOx is enhancing treatment purity and efficacy through the Phase 1 clinical trial of AGX-148, which utilizes CD39 and CD103 biomarkers to precisely select CD8+ T cells with high tumor reactivity, rather than simple bulk culture.

Global Solid Tumor Market Leadership and Future Prospects

Grit Bio (China) is promoting the widespread adoption of cell therapy by conducting a pivotal Phase 2/3 clinical trial of GT101, China's first TIL therapy, for cervical cancer, utilizing the StemTexp cell culture platform. The company is also concurrently conducting a Phase 1 clinical trial of GT201, which combines cytokine self-expression gene modification technology, further driving the expansion of the global cell therapy market. With the global TIL therapy market projected to grow to approximately $4.2 billion by 2035, the competition among latecomers to overcome toxicity and enhance efficacy will be a key driver in re-evaluating the value of the cell therapy sector.